Advertisement

What the Intensivist Needs to Know About Leukemia Patients

  • Mahesh Swaminathan
  • Kiran NaqviEmail author
Reference work entry

Abstract

Acute leukemias are devastating diseases. Advancements in antileukemic therapy and early recognition and management of complications have led to improved survival. Some of the life-threatening complications associated with leukemias or from antileukemic treatment include tumor lysis syndrome, hyperleukocytosis with or without leukostasis, diffuse alveolar hemorrhage, and cytokine release syndrome. All the complications mentioned above are associated with significant mortality. It is therefore critical to understand the pathophysiology, early signs and symptoms, and management of these complications.

Keywords

Tumor lysis syndrome Cytokine release syndrome Diffuse alveolar hemorrhage Hyperleukocytosis Acute leukemia 

References

  1. 1.
    Abu-Alfa A, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–13.CrossRefGoogle Scholar
  2. 2.
    Ali MA, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest. Hematol Oncol. 2016;34(2):69–78.CrossRefGoogle Scholar
  3. 3.
    Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. ASH Educ Program Book. 2014;2014(1):457–60.Google Scholar
  4. 4.
    Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel P-L, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry J-E, Récher C. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 2018;103:988–98.CrossRefGoogle Scholar
  5. 5.
    Cairo MS, Coiffier B, Reiter A, Younes A, Panel TLSE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.CrossRefGoogle Scholar
  6. 6.
    Chen KH, Liu HC, Liang DC, Hou JY, Huang TH, Chang CY, Yeh TC. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. J Formos Med Assoc. 2014;113(11):833–8.CrossRefGoogle Scholar
  7. 7.
    Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30(4):336–40.CrossRefGoogle Scholar
  8. 8.
    Garimella PS, Balakrishnan P, Ammakkanavar NR, Patel S, Patel A, Konstantinidis I, Annapureddy N, Nadkarni GN. Impact of dialysis requirement on outcomes in tumor lysis syndrome. Nephrology (Carlton). 2017;22(1):85–8.CrossRefGoogle Scholar
  9. 9.
    Inaba H, Pui C-H. Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone. Lancet Oncol. 2010;11(11):1096–106.CrossRefGoogle Scholar
  10. 10.
    Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.CrossRefGoogle Scholar
  11. 11.
    Lichtenberger JP 3rd, Digumarthy SR, Abbott GF, Shepard JA, Sharma A. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol. 2014;43(3):128–39.CrossRefGoogle Scholar
  12. 12.
    Mamez A-C, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, Schlemmer B, Dombret H, Azoulay E, Lengliné E. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leuk Lymphoma. 2016;57(10):2281–8.CrossRefGoogle Scholar
  13. 13.
    Mataix R, Gomez-Casares MT, Campo C, Jimenez S, Malcorra JJ. Acute leg ischaemia as a presentation of hyperleukocytosis syndrome in acute myeloid leukaemia. Am J Hematol. 1996;51(3):250.CrossRefGoogle Scholar
  14. 14.
    Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent M, Martínez D, Ortí G, Algarra L, Martínez J, Moscardó F, Javier de la R, Jarque I, Sanz G, Sanz M. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.CrossRefGoogle Scholar
  15. 15.
    Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2017;15:47.CrossRefGoogle Scholar
  16. 16.
    Novetny JR, Müller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Dührsen U. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol. 2005;74(6):501–10.CrossRefGoogle Scholar
  17. 17.
    Park MS. Diffuse alveolar hemorrhage. Tuberc Respir Dis. 2013;74(4):151–62.CrossRefGoogle Scholar
  18. 18.
    Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9(4):e95062.CrossRefGoogle Scholar
  19. 19.
    Piccirillo N, Laurenti L, Chiusolo P, Sorà F, Bianchi M, De Matteis S, Pagano L, Zini G, d’Onofrio G, Leone G, Sica S. Reliability of leukostasis grading score to identify high risk patients with hyperleukocytic leukemia. Blood. 2008;112(11):2979.Google Scholar
  20. 20.
    Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18.CrossRefGoogle Scholar
  21. 21.
    Robbins RA, Linder J, Stahl MG, Thompson AB 3rd, Haire W, Kessinger A, Armitage JO, Arneson M, Woods G, Vaughan WP, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med. 1989;87(5):511–8.CrossRefGoogle Scholar
  22. 22.
    Ruggiero A, Rizzo D, Amato M, Riccardi R. Management of hyperleukocytosis. Curr Treat Options Oncol. 2016;17(2):7.CrossRefGoogle Scholar
  23. 23.
    Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.CrossRefGoogle Scholar
  24. 24.
    Sisson JH, Thompson AB, Anderson JR, Robbins RA, Spurzem JR, Spence PR, Reed EC, Armitage JO, Vose JM, Arneson MA, et al. Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease. Am Rev Respir Dis. 1992;146(2):439–43.CrossRefGoogle Scholar
  25. 25.
    Slats AM, Egeler RM, van der Does-van den Berg A, Korbijn C, Hählen K, Kamps WA, Veerman AJP, Zwaan CM. Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia. 2005;19:537.CrossRefGoogle Scholar
  26. 26.
    Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155–61.CrossRefGoogle Scholar
  27. 27.
    Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T, Fujisaki T, Takeda K, Nakajima A, Ueda T. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016;21(5):996–1003.CrossRefGoogle Scholar
  28. 28.
    Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79.CrossRefGoogle Scholar
  29. 29.
    Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations